Population based studies

基于人群的研究

• 批准号: 8349394
• 负责人: Carl Ola Landgren
• 金额: $ 19.86万
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8349394
• 关键词: Affect; Biological Assay; Biological Markers; Chronic Lymphocytic Leukemia; Clinical; Disease; Early treatment; Future; Goals; Individual; Intervention; Intervention Studies; Knowledge; Modeling; Monoclonal gammopathy of uncertain significance; Multiple Myeloma; Patients; Preclinical Drug Evaluation; Research; Sampling; Testing; biobank; disease mechanisms study; improved; in vitro Model; population based; programs; prospective; tumor progression

Using population-based approaches and biomarker assays on stored samples (in exisiting large biobanks) allows my research to move forward more quickly. I can use these strategies in parallel with my clinical program - to test important questions and to identify candidate assays and targets. In parallel, I develop prospective patient studies for individuals affected with myeloma precursor disease, early intervention studies (MGUS and smoldering myeloma), and targeted myeloma treatment studies. By taking these parallel approaches, and by constantly developing and improving our concepts, I bevieve that we will be able to delay progression and ultimately cure patients from myeloma in the future. Currently, we are developing in vitro models. The aim of this effort is to develop models to study mechanisms of disease, and to allow us to do drug screening.

使用基于人群的方法和在存储样本上的生物标志物测定（在大型生物库中）可以使我的研究更快地前进。我可以与我的临床计划并行使用这些策略 - 测试重要问题并确定候选分析和目标。同时，我针对患有骨髓瘤前体病，早期干预研究（MGUS和闷烧骨髓瘤）的患者进行了前瞻性患者研究，并针对骨髓瘤治疗研究。 通过采用这些平行的方法，并不断发展和改善我们的概念，我认为我们将能够延迟进展并最终使患者从未来的骨髓瘤治愈。 目前，我们正在开发体外模型。这项工作的目的是开发研究疾病机制的模型，并允许我们进行药物筛查。